Comparative Pharmacology
Head-to-head clinical analysis: QDOLO versus TRAMADOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QDOLO versus TRAMADOL.
QDOLO vs Tramadol
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Tramadol is a centrally acting synthetic opioid analgesic that binds to μ-opioid receptors and inhibits the reuptake of norepinephrine and serotonin, modulating pain transmission.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
50-100 mg orally every 4-6 hours as needed for pain; maximum 400 mg/day. For moderate to severe pain, 50-100 mg IV or IM every 4-6 hours; maximum 600 mg/day.
None Documented
None Documented
Clinical Note
moderateTramadol + Torasemide
"The risk or severity of adverse effects can be increased when Tramadol is combined with Torasemide."
Clinical Note
moderateTramadol + Etacrynic acid
"The risk or severity of adverse effects can be increased when Tramadol is combined with Etacrynic acid."
Clinical Note
moderateTramadol + Furosemide
"The risk or severity of adverse effects can be increased when Tramadol is combined with Furosemide."
Clinical Note
moderateTramadol + Bumetanide
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life: approximately 6.3 hours (range 5-9 hours) for tramadol; active metabolite M1 has half-life ~7-9 hours. Clinically, dosing interval is typically every 4-6 hours.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Primarily renal (90%): ~30% as unchanged drug, ~60% as metabolites. Biliary/fecal: ~10%.
Category C
Category D/X
Opioid Agonist
Opioid Agonist
"The risk or severity of adverse effects can be increased when Tramadol is combined with Bumetanide."